Biib stock zacks
Biogen (BIIB, $336.64) was one of the top gainers for the month, rising +17.22% to $336.64 per share.A.I.dvisor analyzed 367 stocks in the Biotechnology Industry for the month ending February 20, 2020 and discovered that 156 of them (42.5%) exhibited an Uptrend while 211 of them (57.5%) exhibited a Downtrend. A.I.dvisor found 144 similar cases when BIIB 's price went up 10% within one month. Quotes delayed at least 15 minutes. Real-time quotes provided by BATS BZX Real-Time Price.Market Data provided by Interactive Data (Terms & Conditions).Powered and Implemented by Interactive Data Looking at the BIIB split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Biogen shares, starting with a $10,000 purchase of BIIB, presented on a split-history-adjusted basis factoring in the Ten years of annual cash flow statements for Biogen (BIIB). The cash flow statement is a summary of the cash inflows and outflows for a business over a given period of time. The cash flows are grouped into three main categories: cash flow from operations, cash flow from investing and cash flow from financing. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis
BIIB: Biogen Inc broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment View All Zacks #1 Ranked Stocks.
Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors to be skeptical. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Earnings estimates for BIIB from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Get free trial access to our live API and historical testing files now! with fundamental company data provided by Morningstar and Zacks Investment Research.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
The stock holds a Zacks Rank #3 (Hold), which indicates expectations of in-line performance from the company in the near term. However, Biogen is enjoying bullish analyst sentiment, as indicated
Preferred stock is a special equity security that has properties of both equity and debt. Biogen's preferred stock for the quarter that ended in Mar. 2020 was $0 Mil.. The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.Biogen's Enterprise Value for the quarter that ended in Mar. 2020 was $57,260 Mil.
Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors to be skeptical. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Earnings estimates for BIIB from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Get free trial access to our live API and historical testing files now! with fundamental company data provided by Morningstar and Zacks Investment Research. Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has increased by 4.2% and is now trading at $306.72. View which stocks have been most impacted by Coronavirus. Webull Financial LLC is a member of Securities Investor Protection Corporation (SIPC), which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash). Explanatory brochure available upon request or at www.sipc.org .
Earnings estimates for BIIB from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Get free trial access to our live API and historical testing files now! with fundamental company data provided by Morningstar and Zacks Investment Research.
Source: Zacks Investment Research May 20, 2020 Nothing Will Stop Biogen Stock From Moving Higher The Alzheimer's-drug delay disappointed Biogen stock owners, but the long-term outlook for the company remains solid. Biogen Inc. BIIB reported fourth-quarter 2019 earnings per share of $8.34, which comprehensively beat the Zacks Consensus Estimate of $8.00. Earnings rose 19% year over year, backed by higher Incyte currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Biogen Inc. (BIIB) : Free Stock Analysis Report Biogen Idec's (BIIB) second quarter EPS of $1.82 was well above the Zacks Consensus Estimate of $1.56 and the year-ago EPS of $1.35. Higher revenues and a lower share count boosted earnings. BIIB Description — Biogen Inc. Based on data provided by Zacks Investment Research via Quandl.com. Get the Zacks research report on BIIB — FREE. BIIB — Performance: PARTNER NEWS: Fri, May 8, 8:23 AM, Zacks Globus Medical (GMED) Misses on Q1 Earnings and Revenues Get the latest Biogen Inc BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Biogen Inc. - BIIB - Stock Price Today - Zacks BIIB is up today, Zacks' proprietary data indicates that Biogen Inc. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the BIIB shares relative to the market in the next few